Reporting owner · CIK 0001936799
Sumner Michael John
Visual SEC Form 4 history across 1 companies, 11 transactions and 3 filings.
CMOChief Medical OfficerINOVIO PHARMACEUTICALS, INC.
Open-market mix
—buys
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #79416 | INO | Sumner Michael John | CMO | grant | 29.6k | $0 | A | 03/05 | 03/04 |
| #79415 | INO | Sumner Michael John | CMO | grant | 36.8k | $0 | A | 03/05 | 03/04 |
| #79408 | INO | Sumner Michael John | CMO | exercise | 11.5k | $0 | M | 02/27 | 02/26 |
| #79407 | INO | Sumner Michael John | CMO | exercise | 5.01k | $0 | M | 02/27 | 02/26 |
| #79406 | INO | Sumner Michael John | CMO | withholding | 3.90k | -$698k | F | 02/27 | 02/26 |
| #79405 | INO | Sumner Michael John | CMO | exercise | 11.5k | — | M | 02/27 | 02/26 |
| #79404 | INO | Sumner Michael John | CMO | exercise | 5.01k | — | M | 02/27 | 02/26 |
| #159403 | INO | Sumner Michael John | CMO | grant | 34.6k | $0 | A | 02/28/2025 | 02/27/2025 |
| #159402 | INO | Sumner Michael John | CMO | grant | 42.9k | $0 | A | 02/28/2025 | 02/27/2025 |
| #159401 | INO | Sumner Michael John | CMO | exercise | 5.01k | $0 | M | 02/28/2025 | 02/26/2025 |
Latest Form 4 facts
Quick context from source filings
Latest transaction
No latest transaction fact is available.
Latest buy
No open-market insider purchase is available.
Latest sale
No open-market insider sale is available.
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
4 observations · Feb 26, 2025 – Feb 26, 2026. Window ends at the latest available report, not today.
Selected observation · Feb 26, 202630,507 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Feb 26, 2025 | 13,229 | Feb 28, 2025 | View transaction |
| Feb 26, 2026 | 22,860 | Feb 27, 2026 | View transaction |
| Feb 26, 2026 | 34,410 | Feb 27, 2026 | View transaction |
| Feb 26, 2026 | 30,507 | Feb 27, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
No open-market purchases or sales in this history.
Net value flow
Buys minus sells
Feb 25
$0
Feb 26
$0
Mar 26
$0
Transaction texture
Ownership and ticket size
Average P/S size—
Median P/S size—
Direct11
Indirect0
Mar 04, 2026grant
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Visual map of known reporting history
Sumner Michael John Insider Activity FAQ
SEC Form 4 context
Who is Sumner Michael John?
Sumner Michael John is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001936799.
Which companies has Sumner Michael John reported transactions for?
INOVIO PHARMACEUTICALS, INC.
When was Sumner Michael John's latest insider buy?
No open-market insider purchase is available for this period.
When was Sumner Michael John's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.